Chris King

Chris King has extensive work experience in the field of nonclinical development and clinical pharmacology. Chris is currently working as the VP of Nonclinical Development & Clinical Pharmacology at Monte Rosa Therapeutics since January 2021. Before that, they were the Head of Nonclinical Development at Disc Medicine from January 2020 to January 2021. Prior to that, Chris held the position of Senior Director of Nonclinical & Clinical Pharmacology at Arena Pharmaceuticals, Inc. from December 2017 to January 2020. Chris also has experience in executive roles, such as Executive Director - DMPK & BD at PharmAkea Therapeutics from November 2012 to February 2018 and Executive Director - DMPK at Bristol-Myers Squibb, San Diego (formerly Amira Pharmaceuticals) from September 2011 to September 2012. Chris's earlier career includes roles at Amira Pharmaceuticals as Director, Senior Director, and Executive Director of DMPK from June 2006 to September 2011. Chris began their career as a Group Leader in ADME at Johnson & Johnson from October 2004 to June 2006 and as a Research Fellow in DMPK at Merck from October 1998 to October 2004.

Chris King earned a Bachelor of Science degree in Biology/Biological Sciences from Beloit College, where they attended from 1989 to 1993. Chris later pursued a PhD in Pharm/Tox at the University of Iowa Roy J. and Lucille A. Carver College of Medicine from 1994 to 1998. In 2001, they obtained an MBA in General Studies from CSUSM College of Business, having completed their studies in 2003.